AINewsnow

Orakl Oncology raises $34M Series A to predict cancer drug results with AI

This story is from 2026-11-12. It is preserved in the archive; the latest stories are on the live feed.

Paris-based Orakl Oncology raised a $34M Series A co-led by Norrsken VC and Singular. The startup grows copies of patients' tumours in the lab, tests drugs on them and uses AI to predict trial results.

Read the full story at The Next Web ↗

Timeline · 1 report

  1. 2026-11-12 17:31 · The Next Web
    Orakl Oncology raises $34M to predict cancer drug results with AI

More stories

  1. Jensen Huang resigns as Nvidia CEO after 33 years, discusses comeback with allies — Hard Fork (NYT)
  2. Researchers allege Chinese AI models were trained on export-banned Nvidia Blackwell chips — Bloomberg AI
  3. Apple to unveil Siri AI smart glasses at WWDC, with Face ID coming to iPhone Duo 2 — Tom's Guide AI
  4. GPT-6 Astra aids detailed proof of candidate lattice definition of Standard Model — OpenAI News
  5. OpenAI launches science blog to share AI research findings — OpenAI News
  6. Grounded flights, Microsoft outage and AI turmoil fuel fears of wider tech breakdown — Washington Post AI
  7. Hydra-PSIE expands 'Coeziune OM–IA' DOI registry to 66 published works — DEV Community — AI
  8. Anthropic's $1.4 trillion IPO to test AI trade amid market turbulence — CNBC Technology

Get the daily brief of stories like this at 6:30 every morning →